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Summary
The intracellular distribution of the enzyme 5-lipoxygenase (5-LO) and 5-lipoxygenase-activating
protein (FLAP) in resting and ionophore-activated human leukocytes has been determined using
immuno-electronmicroscopic labeling of ultrathin frozen sections and subcellular fractionation
techniques. 5-LO is a 78-kD protein that catalyzes the conversion ofarachidonic acid to leukotrienes.
FLAP is an 18-kD membrane bound protein that is essential for leukotriene synthesis in cells.
In response to ionophore stimulation, 5-LO translocates from a soluble to a sedimentable fraction
of cell homogenates. In activated leukocytes, both FLAP and 5-LO were localized in the lumen
of the nuclear envelope. Neither protein could be detected in any other cell compartment or
along the plasma membrane. In resting cells, the FLAP distribution was identical to that observed
in activated cells. In addition, subcellular fractionation techniques showed >83% of immuno-
blot-detectable FLAP protein and -64% of the FLAP ligand binding activity was found in
the nuclear membrane fraction. A fractionation control demonstrated that a plasma membrane
marker, detected by a monoclonal antibody PMN13F6, was not detectable in the nuclear membrane
fraction. In contrast to FLAP, 5-LO in resting cells could not be visualized along the nuclear
envelope. Except for weak labeling of the euchromatin region of the nucleus, 5-LO could not
be readily detected in any other cellular compartment. These results demonstrate that the nuclear
envelope is the intracellular site at which 5-LO and FLAP act to metabolize arachidonic acid,
and that ionophore activation of neutrophils and monocytes results in the translocation of 5-LO
from a nonsedimentable location to the nuclear envelope.
eukotrienes are products of arachidonic acid metabolism
that are produced by leukocytes and that have a variety
of effects on the immune system (1). The enzyme 5-lipox-
ygenase (5-LO,1 EC 1.13.11.12) catalyzes two key steps in the
leukotriene biosynthetic pathway (2, 3). These steps are the
oxygenation ofarachidonate to 5-(S)-hydroperoxy-6,8, 11,14-
eicosatetraenoic acid (5-HPETE), followed by its dehydroge-
nation, which results in the formation of the unstable epoxide
LTA4. In neutrophils the enzyme LTA4 hydrolase then con-
verts LTA4 to LTB4, which is a potent chemotactic and ac-
tivating factor for neutrophils and eosinophils (4-6). In eo-
1 Abbreviations used in this paper. FLAP, 5-lipoxygenase-activating protein;
GAM, goat anti-mouse IgG; GAR, goat anti-rabbit IgG; 5-HPETE,
5-(S)-hydroperoxy-6,8,11,14-eicosatetraenoic acid; 5-LO, 5-lipoxygenase;
LSM, lymphocyte separation medium; PLP, paraformaldehyde-lysine-
periodate.
sinophils and mast cells, LTA4 can also be converted to LTC4,
LTD4, and LTE4, all of which stimulate contraction of vas-
cular and bronchial smooth muscle (7, 8), resulting in effects
on local circulation and bronchoconstriction. These potent
biological effects implicate leukotrienes in a number of hyper-
sensitivity and inflammatory disorders, including asthma and
inflammatory bowel disease (9-12).
The enzyme 5-LO has been purified from a number ofmam-
malian leukocyte sources (2, 3, 13). In every case the purified
enzyme was activated by calcium and ATP. It was observed
that when subcellular fractions of unstimulated human leu-
kocytes were examined for 5-LO distribution, >90% of the
immunodetectable enzyme was found in the 100,000-g su-
pernatant fraction. However, in response to challenge with
the calcium ionophore A23187, 5-LO translocated from a su-
pernatant fraction to a sedimentable fraction (2, 14), strongly
suggesting that membrane association plays a key role in the
in vivo regulation of 5-LO activity.
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have led to the identification of an 18-kD membrane-bound
protein, 5-lipoxygenase-activating protein (FLAP), which has
an essential role in the regulation of cellular 5-LO-activity
(15). Observation of the cell and tissue distribution of 5-LO
andFLAP hasindicatedthat both oftheseproteins arepresent
in all leukotriene producing cells analyzed thus far (16). Fur-
ther evidence demonstrating that FLAP is essential for5-LO
activity in intact cells comes from transfection experiments
that showed that cellslackingeither protein must be cotrans-
fected with cDNAsfor both in order to produce leukotrienes
in response to calcium ionophore stimulation (17) .
At present there are no reports describing the ultrastruc-
tural localization of FLAP andconflicting reports describing
thelocalization of5-LO. Ultrastructural studies have reported
that in leukocytes 5-LO waslocalized in the cytoplasm (18),
whereas it was associated with the nuclear envelope in the
corpus luteum (19) and pancreatic acinar cells (20). Subcel-
lular fractionation studies have found that in human poly-
morphonuclear leukocytes 5-LO was found in the specific
granules (21). None of these studies addressed the effect of
activation of leukotriene synthesis on the subcellular distri-
bution of5-LO. This report will describe aseries ofimmuno-
electronmicroscopic observations and subcellular fraction ex-
periments designed to answer the following questions: (a)
what is the subcellular distribution of 5-LO and FLAP in
human leukocytes and (b) what is the ultrastructural corre-
late of the 5-LO translocation event observed after ionophore
activation?
Materials and Methods
Materials.
￿
Rabbit polyclonal antiserum to highly purified 5-LO
(22) wasprepared by Hazelton Research Laboratories (Denver, PA)
by injection of 200 pg of purified 5-LO followed by two boosts
of 100Wg each at 1-mo intervals. Therabbit wasthen bledbiweekly
for 6 mo. Immunoblot analysis showed that all bleeds recognized
a 78-kDprotein present in supernatant fractions ofhuman leuko-
cytes. Thepreparation ofrabbit anti-peptide antiserum specific for
amino acids41-52 of FLAP was as previously described (23). IgG
from these antisera was isolated by chromatography over Protein
A(Pierce, Rockford, IL). PreimmuneIgG was also prepared from
these rabbits. Mousepolyclonal antiserum specific for human 5-LO
was obtained by immunizing mice with purified human 5-LO (24).
H52, a hybridoma producing a monoclonal antibody specific for
CD18 (25), was obtained from the Developmental Studies Hy-
bridomaBank (Baltimore, MD) and PMN13F6 ascites fluid con-
taining a monoclonal antibody specific for a PMN plasma mem-
brane protein (26, 27) was purchased from Sigma Chemical Co.
(St. Louis, MO). Dextran T500 was from Pharmacia AB (Upp-
sala, Sweden), Dulbecco's PBSeither with or withoutcalciumand
magnesium and ACK lysis buffer were from Gibco Laboratories
(Grand Island, NY). Lymphocyte separation medium (LSM) was
from Organon TeknikaCorp.(Durham, NC).Colloidal gold probes
(5 and 10 nm) conjugated with either goat anti-rabbit IgG (GAR
5 or GAR10) or goat anti-mouse IgG(GAM 5 or GAM 10) were
purchased from Amersham Corp. (Arlington Heights, IL). Sea
Plaque low-gelling temperature agarose was obtained from FMC
BioProducts (Rockland, ME). Glutaraldehyde andosmium tetroxide
were from Electron Microscopy Sciences (Fort Washington, PA),
paraformaldehyde was from Fisher Scientific (Fair Lawn, NJ) and
A23187 and DMSO and other chemicals were of reagent grade
and were obtained from SigmaChemical Co. Recombinant 5-LO
wasprovided by Dr. Denis Riendeau,MerckFrosst, Pointe Claire-
Dorval, Canada.
Isolation, Fixation, andFreezing ofHuman Peripheral BloodMono-
cytes andPMN. Leukocytes were isolated from venous blood of
normal human volunteers by dextran sedimentation followed by
centrifugation throughLSM andhypotoniclysis to remove residual
erythrocytes (22). The resulting PMN were then washed in PBS
withoutcalciumandmagnesium. Monocytes, which collectin the
boundary layer between LSM and the overlaying PBS, were also
harvested. Final cell pellets were resuspended in Dulbecco's PBS
containing calcium andmagnesium at a cell concentrationof 2-4
x 106cells per ml. In certain experiments cells were activated by
incubation in 5 ug/mlof thecalciumionophoreA23187 for 5 min
at 37°C before subsequent processing.
Afterisolation, andin some experiments, activation, N5 x 106
cells suspended in a total volume of 2.5 ml of ice cold PBS were
mixedwith an equal volume ofa2x fixative prepared to yieldfinal
concentrations of0.05% glutaraldehyde, 3.5% paraformaldehyde,
and 0.1 M sucrose in PBS, pH 7.3. This mixture was irradiated
in a microwave oven for a period (typically 20-22 s) sufficient to
raise thetemperature of thesuspension to 45°C (28). Afterirradia-
tion theglutaraldehyde wasimmediately quenched by theaddition
of 10 ml of paraformaldehyde-lysine-periodate (PLP) fixative (29).
The quenched cells were washed twicein additional PLP andfixa-
tion was continued in PLP overnight at 4°C. The following
morning, the fixed cells were pelleted by centrifugation at 1000
g for 5 min andresuspended in 1 ml of PBS containing 0.1 M su-
crose. These cells were mixed with an equal volume of 2% low-
gelling temperature agarose andpelleted in 400-ul pointed micro-
fuge tubesin a prewarmed swinging bucket microfuge rotor such
that thecells formed a tightpellet before the agar hardened. Typi-
cally 3-6 x 106 cells were divided into 10 pellets at this point.
The agar embedded cells were cryoprotected by infiltration for 90
min with 2.3 M sucrose in phosphate buffer, pH 7.2 containing
50% polyvinylpyrrolidone (30) afterwhichthey were mountedon
aluminum nails and frozen by injection into liquid propane at
-185°Cin a freezing apparatus(Model KF-80; Reichert Scientific
Instruments, Buffalo, NY). Frozen sampleswere then stored under
liquid nitrogen until use. In certain experiments, cells were fixed
for 30 minin 0.01% glutaraldehyde/3.0%paraformaldehyde in PBS
or overnightin PLP fixative. However themorphology ofthefinal
sections obtained with thesefixations was inferior to that obtained
with the microwave/glutaraldehyde/PLP procedure. Each experi-
mental observation wasverified in at least threeindependent batches
of cells isolated from different donors.
SDS-PAGE andImmunoblot Analysis.
￿
Human leukocytes were
isolated from buffy coat concentrates (Red Cross, Montreal,
Canada), sonicated, and then fractionated by differential centrifu-
gation as previously described (22). Proteins from the 100,000g
pellet (for FLAP immunoblots, 1.2,ugprotein/lane), from 30-60%
ammonium sulfateprecipitated 10,000-g supernatant fractions (22)
(for rabbit anti-5-LOblots, 12,ugprotein/lane)or purified human
5-LO (for mouse anti-5-LOblots, 0.5 ug/lane) were separated by
SDS-PAGE. Separated proteins were electrophoretically transferred
to nitrocellulose overnight at 100 mA usinga Noveximmunoblot
apparatus (Novel Experimental Technology, San Diego, CA). Im-
munoblot analysis wasthen carried outas previously described (16)
using: (a)Protein Apurified IgGs at adilution equivalent to a 1/200
dilution ofunpurified antisera forrabbit anti-FLAPIgGandrabbit
anti-5-LO IgG andtheircorresponding preimmune IgGs; and (b)
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serum. 1251-Protein A (NEN-Dupont, Mississauga, Ont., Canada)
was used to detect boundantibodies. In thecase ofmouseantisera,
thetransfers were also incubated with a 1/500dilution of affinity
purified goat anti-mouse IgG(Cappel, Scarborough, Ont., Canada)
before incubation with 1251-Protein A.
For immunoblot analysis of subcellular fractions, the proteins
from each fraction were first concentratedby adding 55 Al icecold
100% TCA to a 500 Al suspension of material. After 30 min at
4°C the precipitated proteins were harvestedby centrifugation for
10 min at 13,000 g at 4°C. The supernatant was discarded and
thepellet resuspended in SDS-PAGE sample buffer, adjusted to neu-
trality with NaOH andboiled before SDS-PAGE.Afterelectropho-
resis, theproteins were transferred to nitrocellulose, whichwas then
cut into strips and incubated with a 1:500 dilution of FLAP an-
tisera or 1:300 dilution of PMN13F6 ascites fluid and processed
as above. The 18-kD bands, corresponding to FLAP, of theresul-
tant autoradiographs were scanned using a 2202 Ultrascan Laser
densitometer (LKB Instruments, Inc., Gaithersburg, MD). Foreach
sample, duplicate 5and10 Al aliquots oftheSDS sample were loaded
on to the gels and in all cases the lanes containing 10 Al had ap-
proximately double the density of the lanes containing 5 pl.
Immunogold Labeling ofCryosections.
￿
Ultrathin cryosectioning
was carried out at -105°C following the techniques of Tokuyasu
(31) on a Reichert Ultracut S ultramicrotome equipped with an
FCScryoattachment. Sections were transferred to hexagonalnickel
grids (200-mesh) that had been coated with formvar and glow
cleaned just before use. All incubations and washing steps were
carriedoutby floating thegrids on droplets of solution dispensed
through0.2 Am syringe filters. Aftertwo 10-min incubations with
1% BSA in PBS containing 0.02% sodium azide (BSA/PBS) to
block nonspecific binding, the sections were incubated overnight
at 4°C with primaryantibody solutions at 5 gg/mlin BSA/PBS.
To demonstrate specificity, in certain experiments theprimary an-
tibodies were preincubated with either recombinant 5-LO or the
peptide corresponding to amino acids 41-52 of FLAP at 10 gg/ml
for 30 min followed by centrifugation at 10,000 g for 10 minbe-
fore incubating the resultant supernatant fraction with sections.
Thefollowingmorning, the sections were washed extensively with
BSA/PBS and then incubatedwith 5- or 10-nm Immunogold probes
for 60 min at room temperature. Anti-rabbit probes were diluted
1:50 andanti-mouse probes were diluted 1:25 in BSA/PBS. After
the gold incubation the grids were again washed extensively in
BSA/PBS, fixedin 2% glutaraldehyde in PBSfor10 min, postfixed
in 2% osmium in H2O for 20 min, stained with 2% uranyl ace-
tate in H2O for 30 min, and finally absorption stained with
0.002%lead citrate in 2% polyvinylalcohol as describedbyTokuyasu
(30). Grids were examined and micrographs taken in an electron
microscope (1000X; JEOL USA, Electron Optics Division, Pea-
body, MA) at 80 kV at an initial magnification of 19,000.
Isolation ofNuclei and FLAP Inhibitor Binding.
￿
A suspension of
leukocytes containing 2 x 10' cells was centrifuged at 500g for
10 min to form a loose pellet which was resuspended in 1 ml of
NP40 lysis buffer (0.1% NP40, 10 mM Tris-HCI, pH 7.4, 10 mM
NaCI, 3 MM MgC12, 1 mM EDTA, and 1 mM PMSF). This sus-
pension was vortexed for 15 s and then centrifuged at 300 g for
10 min at room temperature. The resultant supernatant fraction
(the nonnuclear fraction) was divided into two 500-IAI aliquots,
oneofwhichwasstored at -70°Cfor FLAP binding analysis while
theotherwasprecipitated with TCAandprocessedforSDS-PAGE
and immunoblot analysis. The NP-401ysis pellet fraction (nuclei)
was resuspended in 90 P,1 of DNase 1 buffer (20 mM Hepes, pH
7.5, 5 MM MgC12, 1 mM CaCl2, 1 mM EDTA, and 1 mM
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PMSF) and 10 Al DNase 1 (1 mg/ml) was added and incubated
for 30 minat 37°C. TheDNasetreatednuclei fraction was divided
into two equal 50-P.1 samples. These sampleswere diluted to 1 ml
by theaddition of 950141Hepeslysisbuffer andsonicatedas above.
A 10-Al aliquot of thethis material was observed by light micros-
copy to verify that >95% of the nuclei were lysed. One sample
was then precipitated with TCA and processedfor SDS-PAGE and
immunoblot analysis. Thesecond sample wascentrifuged at 100,000
g for 60 min at 4°C in a TL100 Ultracentrifuge (Beckman In-
struments, Inc., Fullerton, CA). The supernatant containing
nucleoproteins wasprecipitated with TCAand processedforSDS-
PAGE. Thepellet was resuspended in 1 ml Hepeslysis buffer, soni-
cated, precipitated with TCA, and processed for SDS-PAGE.
The FLAP inhibitorbinding assaywas modified from themethod
ofCharleson (32). This assayis basedon theobservation that MK-
886, an indole leukotriene biosynthesis inhibitor, bindswith high
affinity andspecificity to FLAP (15). Aliquots from leukocyteprepa-
rations were resuspended in assay buffer (100 mM Tris-HCI, pH
7.5, 140 mM NaCl, 2 mM EDTA, 0.5 mM dithiothreitol, 5%
glycerol, 0.05% Tween 20). Duplicate assays at two protein con-
centrations foreach sample were performed in Beckman96-deep-
well polypropylene microtiter plates. Bindingwas initiatedby the
addition ofleukocytesamples (1-15Rg protein) to wellscontaining
100 A1 1251-1,691-831 (a radiolabeled analog of MK886), 300-700
pM final concentration, diluted in assay (buffer/methanol, 97:3;
vol/vol) and either 2 Al Me2SO or MK886 in Me2SO (10-s M
final concentration), plus the required volume of assay buffer to
bring the final volume to 200 P,1. The plate was incubated with
shaking for 20 min at room temperature. The samples were then
filtered and washed using a Harvester 96 (Tomtec, Orange, CT)
onto a LKB printed filtermat B, prewettedwith wash buffer (100
mM Tris-HCI, pH 7.5, 0.05% Tween 20). Bound 1,I was deter-
minedin aLKB 1272 Clinigamma Quatro counter. Specific binding
was defined as the difference between binding in the absence and
the presence of 10-s M MK-886.
To quantitate totalFLAP protein andinhibitorbinding present
in whole cells, a second suspension of leukocytes containing 2 x
10' cells was centrifuged at 500 g for 10 min. The pelleted cells
were then resuspended in 1 ml of Hepeslysisbuffer (5 mM Hepes,
pH 7.4, 1 mM EDTA, and 1 mM PMSF). This suspension was
sonicatedon iceby three20 sbursts usingaCole-Palmer 4710 ultra-
sonichomogenizer setat 70% output (Chicago, IL). Celllysis was
checkedvisually andiflysis was not >95% the sample wasresoni-
cated. The complete sonicated suspension was divided into two
500-Al aliquots, stored, and processed for SDS-PAGE and FLAP
inhibitor binding as described above.
Results
Characterization ofAntibody Probes.
￿
The specificity of the
anti-FLAP andanti-5-LO probes used in theimmunolocali-
zation experiments wasverified by immunoblot analysis. Crude
protein fractions from human leukocytes were separated by
SDS-PAGE, transferred to nitrocellulose and analyzed. Fig.
1 demonstrates that anti-FLAPrabbit IgGrecognizes asingle
18-kD protein that has been previously identified as FLAP
(15) . Fig. 1 also shows that rabbit anti-5-LOIgG andmouse
polyclonal 5-LO antiserum bind most predominantly to a
single protein of 78 kD that hasbeen identified as 5-LO (22).
The rabbit antiserum also immunoprecipitated a15S-labeled
78-kD protein from DMSO differentiated HL-60 cells prela-Figure 1 .
￿
Immunoblot characterization of 5-LO and FLAP antibodies .
Human PMN proteins on nitrocellulose strips were incubated with : lane
1, preimmuneIgG (from the anti-FLAP rabbit) ; lane 2, anti-FLAP IgG ;
lane 3, preimmuneIgG (from the anti-5-LO rabbit); lane 4, anti-5-LO
IgG ; lane 5, control mouse serum; and lane 6, mouse anti-5-LO serum,
as described in Materials and Methods . Note that anti-5-LO IgG reacts
with a single band of 78 kD, that anti-FLAPIgG detects a single protein
of 18 kD, and that the preimmune IgGs only react weekly with nonspecific
bands . Also note that mouse anti-5-LO serum detects a band at the migra-
tion position of authentic 5-LO, whereas control mouse serum does not
label this band . Molecular mass markers are shown to the left and the
migration positions of 5-LO (78 kD) and FLAP (18 kD) are indicated .
Total FLAP
inhibitor bound
(prnol/10' cells)
￿
1 .25
￿
0.2
beled with [35S]methionine (24) . The precipitation of this
labeled protein could be completely eliminated by prein-
cubating the anti-5-LO with excess unlabeled purified 5-LO
(Ethier, D., and J . Evans, unpublished data) .
FLAP Is in the Nuclear Envelope of Resting Cells.
￿
To
visualize the intracellular distribution ofFLAP and 5-LO in
resting cells, freshly isolated peripheral blood leukocytes were
fixed and frozen at -185°C . Ultrathin cryosections of the
frozen cells were incubatedwith either anti-FLAPor anti-5-
LO IgG followed by colloidal gold conjugated secondary
probes . Electronmicroscopic observation of the sections in-
cubated with anti-FLAP antibodies revealed that FLAP was
strikingly concentrated in the lumen of the nuclear envelope
of both neutrophils (Fig. 2 A) and monocytes (Fig. 2 B) .
In rare instances anti-FLAP is also observed to label the en-
doplasmic reticulum ofsome monocytes (Fig. 2 B) . This en-
doplasmic reticulum labeling is most likely a reflection of
anti-FLAP binding to newly synthesized, possibly inactive,
FLAP protein, which wouldbe expected to be translated on
rough endoplasmic reticulum . Since cells displaying this
labeling pattern are only rarely observed, it is likely that they
represent a subpopulation of cells that hadbeen partially ac-
tivated in the donor before isolation .
Immunogold labeling wasnot observed along the plasma
membrane or associated with any other membrane structures.
Table 1 .
￿
Immunoblot Analysis' and Quantitation ofFLAP Inhibitor Binding# on Isolated Leukocyte Fractions
' Immunoblot analysis of FLAP and PMN13F6 antigen from whole cell lysates and subcellular fractions of resting human leukocytes was carried
out as described in Materials and Methods . For each determination, identical aliquots containing 5 x 105 cells were either lysed and loaded directly
on to SDS-PAGE gels or fractionated as described in Materials and Methods before immunoblot analysis . The average density of duplicate bands
for each fraction was determined and normalized to the density of the whole cell lysate whichwas defined as yielding 100% . Percentages were calculat-
ed for three separate experiments and are shown ± SD .
I FLAP inhibitor binding to human leukocyte lysate and subcellular fractions were performed as described in Materials and Methods. Three separate
experiments were performed in duplicate and the values were averaged ± SD .
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Whole cell
lysates
Nonnuclear
(300-g supernatant)
Nuclear
(300-g pellet)
Nucleoplasmic
(100,000-g
supernatant)
Nuclear
membrane
(100,000-g
pellet)
Immunoblot
analysis of FLAP 100% 2 ± 3% 141±57% 0±0% 83±39%
Immunoblot
analysis of
PMN13F6 100% 109 ± 56% 3±5% 0±0% 0±0%
FLAP inhibitor bound
(pmol/mg protein) 1.0 ± 0.4 0 .2 ± 0.1 3.3 ± 1.0 0.1 ± 0.1 4.1 ± 0.9In our sections neutrophils were identified by their very
polymorphic nuclei and the presence of large numbers ofchar-
acteristic granules, whereas monocytes had rounder nuclei,
contained fewer granules, and had much more extensive en-
doplasmic reticulum . Sections incubated with anti-5-LO IgG
were devoid of any detectable gold label along either the nu-
clear envelope, the endoplasmic reticulum, or the plasmamem-
brane . In addition, sections of resting leukocytes incubated
with either anti-FLAP or anti-5-LO IgG did not display any
label associated with the Golgi complex, mitochondria, mem-
branebound granules, or within the cytoplasmic ground sub-
stance (Fig. 2 C) . However, there were occasionally a few
gold particles observed over the euchromatin region within
the nucleus of sections incubated with anti-5-LO IgG (Fig.
2 C) . Resting (no treatment before fixation) and sham-treated
(DMSO vehicle only) leukocytes gave identical labeling
patterns.
To confirm the immuno-EM observation (Fig . 2,A and
B) that FLAP was present in the nuclear envelope, we pre-
pared nuclear and cytoplasmic fractions from isolated resting
human leukocytes. The proportion ofFLAP determined by
immunoblot analysis and the distribution of FLAP ligand
binding activity between fractions was then determined . The
immunoblot results, summarized in Table 1, show that FLAP
protein resides predominantly in the nuclear fraction, which
was isolated as a 300-g pellet of NP-40 lysed cells. When
the amount ofFLAP detected in whole cell lysates is defined
as 100%, the nuclear fraction contains 141% of this amount,
whereas the 300-g supernatant fraction only contains 2% .
If the nuclear fraction was further divided into nuclearmem-
brane and nucleoplasm fractions by sonication of the 300-g
nuclear pellet followed by a 100,000-g centrifugation step,
83% of the amount present in the whole cell lysate was re-
covered in the 100,000-g pellet whereas0% remained in the
supernatant fraction . As a fractionation control, a similar anal-
ysis was carried out utilizing PMN13F6, an antibody that
recognizes a neutrophil plasma membrane protein (26, 27) .
This control (Table 1) showed that <3% of the PMN13F6
antigen was found in the nuclear fraction, indicating that
the separation of nuclei and plasmamembrane was clean. The
apparent increase in the absolute amount ofFLAP in the nu-
clear fraction relative to the whole cell fraction may be an
artifact of the quantitation procedures since the whole cell
pellets were more difficult to disperse in sample buffer, or
may be the result of increased antigenicity of FLAP in the
Figure 2 .
￿
Immunogold labeling ofultrathin frozen sections ofresting
leukocytes incubated with anti-FLAP IgG (A, B) or anti-5-LO IgG (C) .
Note that FLAP immunogold label (arrowheads) is concentrated within
the lumen of the nuclear envelope in neutrophils (A) and along the nu-
clear envelope and endoplasmic reticulum ofmonocytes (B) . In B it is par-
ticularly clear that thenuclear envelope is contiguous with the endoplasmic
reticulum (arrow). Ultrathin frozensections ofresting leukocytes incubated
with anti-5-LO display only a small number of gold particles over the
euchromatin region ofthe nucleus (arrowheads, C) . The lengths ofnuclear
envelope delineated by brackets arerepresentative ofwell-preserved regions
in which both the inner and outer leaflet of the nuclear envelope can be
clearly observed . These and similar lengths from additional micrographs
were analyzed to provide the data presented in Tables 1-3 . Nuc, nucleus,
gr, granule, bar, 100 run .nuclear fraction. It is also possible that the proteins in the
whole cell fraction may have been more susceptible to pro-
teolysis than the NP-40 lysed fractions .
The results ofFLAP inhibitor binding experiments (Table
1) also demonstrate that -64% (0.8/1.25) of the FLAP in-
hibitor binding activity fractionates with the nuclei and the
vast majority of this nuclear material was associated with the
nuclear membrane (4.1 vs. 0.1pmol/mg protein) . Thus, results
of both immunoblot quantitation of FLAP protein and di-
rect binding ofiodinated FLAP inhibitor confirm the immuno-
EM observation that FLAP is concentrated in the nuclear
envelope of resting leukocytes .
FLAP and 5-LO Are in the Nuclear Envelope o,f Activated
Cells. To determine the effect of activation on the intracel-
lular distribution ofFLAP and 5-LO, freshly isolated leuko-
cytes were incubated with the calcium ionophore A23187 be-
fore fixation, freezing, cryosectioning, and immunolabeling .
As in resting cells, sections incubated with anti-FLAP anti-
bodies displayed immunogold labeling within the lumen of
the nuclear envelope (Fig. 3, A and B) . Moreover, in marked
contrast to resting cells, ionophore-activated cells incubated
with anti-5-LO IgG displayed immunolabeling within the
lumen of the nuclear envelope (Fig . 3, C and D) . This pat-
tern was very similar to that obtained with anti-FLAP anti-
bodies . Both antibodies also occasionally labeled the en-
doplasmic reticulum . However, the density of gold particles
observed here was much less concentrated than that found
in the lumen of the nuclear envelope (data not shown) . Nei-
ther antibody yielded any significant labeling of the plasma
membrane, nucleus (exclusive ofthe nuclear envelope), Golgi
complex, mitochondria, membrane bound granules, or cy-
toplasmic ground substance . Similar patterns of 5-LO and
FLAP distribution were observed in both neutrophils and
monocytes. In addition, with either probe there was very little
background labeling observed outside of the cells .
In an effort to quantitate the preceding observations, the
number of gold particles observed along measured lengths
ofthe nuclear envelope were counted (Table 2) . These results
show that in cells labeled with anti-FLAP IgG there were
12 and 17 particles/Am, in resting and activated cells, respec-
tively. In cells labeled with anti-5-LO there were 1 and 11
particles/Am, in resting and activated cells, respectively. This
analysis underscored the dramatic increase in 5-LO labeling
that calcium ionophore activation produced in these cells . It
also suggested that activation did not have any significant
effect on the distribution or density ofFLAP labeling. It should
also be noted that for the purposes ofthis analysis only regions
ofthe nuclear envelope that were very well preserved, in which
both the inner and outer lipid bilayers were evident and in
which the lumen was not dilated were considered . Examples
of typical areas included for this analysis are delineated by
brackets in Figs. 2 and 3 .
Figure 3 .
￿
Immunogold labeling of ultrathin frozen sections ofionophore activated neutrophils incubated with anti-FLAP IgG (A, B) or anti-5-L0
IgG (C, D) . Both FLAP and 5-LO antibodies label the lumen of the nuclear envelope (arrowheads). Gold particles are not observed associated with
the plasma membrane (pm), or membrane bound cytoplasmic granules (gr) . Neither IgG appears to label the nuclear matrix or the cytoplasmic ground
substance. Lengths of nuclear envelope delineated by brackets are typical of those analyzed to provide the data presented in Table 2 . Nuc, nucleus,
er, endoplasmic reticulum, bar, 100 nm .
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￿
Quantitation of Anti-FLAP and Anti-5-LO labeling
of the Nuclear Membrane in Activatedand Sham-treated Leukocytes'
Sham-treated Ionophore-activated
anti-FLAP
￿
12.3 ± 5 .9 (8)
￿
16.8 ± 7.8 (9)
anti-5-LO
￿
0.9 ± 0.26 (21)
￿
11 .1 ± 3.5 (8)
Data presented as the mean number of particles//tm ± SD (number
of cells counted).
The distribution of immunogold particles within the nu-
clearenvelope was also quantitated in a similar manner (Table
3). In this analysis gold particles were counted as being as-
sociated with either the inner or the outer nuclear membrane
if they were touching or within one particle diameter of that
membrane. Other particles, not within one diameter of ei-
ther membrane but still within the lumen, were considered
to be luminal. Particles that appeared to be outside of either
membrane were not included in this analysis. The results show
that both FLAP and 5-LO were relatively more concentrated
on the inner nuclear membrane than on either the outer mem-
brane or within the lumen. The distribution of 5-LO was
heavily skewed toward the inner nuclear membrane; 50% of
the bound gold particles were observed associated with the
inner membrane, <40% appeared to be in the lumen, and
x+10% were associated with the outer membrane. FLAP
staining was also more often associated with the inner mem-
brane; >40% of the immuno-FLAP gold particles were local-
ized on the inner membrane, -25% of the label appeared
to be in the lumen, and <30% was associated with the outer
nuclear membrane. In this analysis, it was implicitly assumed
that both 5-LO and FLAP were associated with a membrane
after activation as was suggested by subcellular fractionation
experiments (14, 33). Thus, immunogold particles that were
counted as being in the lumen were probably physically as-
sociated with either the inner or outer nuclear membranes,
but could not be unambiguously assigned as beingassociated
with either. Therefore, it was likely that an even higher propor-
tion of both 5-LO and FLAP were associated with the inner
nuclear membrane than was reflected by these data.
In a related experiment, carried out to determine if FLAP
Inner
membrane
Anti-FLAP
￿
41.8 ± 18.0%
Anti-5-LO
￿
49.8 ± 11 .3% t
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or 5-LO was expressed at the plasma membrane, freshly iso-
lated, ionophore activated cells were incubated with FLAP
or 5-LO antibodies before fixation. This incubation was car-
ried out at 4°C in order to eliminate the possibility of en-
docytosis of surface bound antibody. After fixation and pro-
cessing, sections were incubated with immunogold probes.
An additional objective of this approach was to determine
if fixation inhibited immunolabeling of putative cell-surface
FLAP or 5-LO epitopes. The results of this experiment were
that no surface bound gold label could be detected on cells
incubated with these antibodies before fixation. However, if
the same sections were incubated with anti-FLAP or anti-5-
LO antibodies aftersectioning, the nuclear envelope was clearly
labeled (data not shown) .
5-LO and FLAP Can Be Colocalized in the Nuclear Enve-
lope Double labelexperiments were performed to verify that
both 5-LO and FLAP were present within the same cellular
compartment at the same time. In these experiments cryosec-
tions of A23187 activatedleukocytes were first incubated with
a mixture of mouse anti-5-LO and rabbit anti-FLAP anti-
bodies, followed by a mixture of the species specific im-
munoprobes GAM 10 and GAR 5. It is important to note
that these two gold probes are sufficiently different in size
to be readily distinguished in the electronmicroscope. The
resulting doubly stained micrographs (Fig. 4) showed that
both 5-LO and FLAP epitopes were present within the nu-
clear envelope of the same cells. Both probes were observed
clustered together in close proximity (Fig. 4, boxedarea) but
were also found randomly scattered within these compart-
ments. This demonstrates that FLAP and 5-LO canbe simul-
taneously observed within the same compartments at the same
time and are often in close proximity to one another. Iden-
tical results were obtained if GAM 5 and GAR 10 were used
instead of GAM 10 and GAR 5. As a further control for
the double label protocol, cryosections were incubated with
only one of the primary antibodies followed by the mixture
of both gold probes. In these cases only the appropriately
sized gold probes bound to the sections, demonstrating that
the localization of the secondary reagents was specific for the
the primary reagents (data not shown).
Demonstration ofSpecificity ofAntibody Labeling.
￿
A number
of control experiments were carried out to demonstrate that
the labeling patterns described above were specific. In many
Table 3.
￿
Distribution of Anti-FLAP and Anti-5-LO Label Across Nuclear Envelope of Activated Leukocytes'
Outer
Lumen
￿
membrane
24.4 ± 15 .8%
￿
27.4 ± 10.0%
39.1 ± 14.8%S
￿
11.0 ± 14.7%ts
' Percentage of gold particles within one particle diameter of the luminal face of the inner or outer nuclear membrane. All particles not within
one diameter of either membrane were counted as being in the lumen. At least eight different cells were counted for each condition.
t Significantly different from each other, p <.005.
S Significantly different from each other, p <.025.of our immunolocalization experiments a group of sections
were incubated with a monoclonal IgG specific for CD18
(clone H52) rather than for FLAP or 5-LO epitopes. The
results with this antibody (Fig. 5) showed that CD18 was
localized in granules and on the plasma membrane in neu-
trophils and monocytes, but was absent from the nuclear enve-
lope and the endoplasmic reticulum . Similar CD18 patterns
have been previously reported (34-36) . Since this pattern was
obtained using the same immunogold reagent as was used
in the double label experiment (GAM 5), it indicates that
the labeling of the nuclear envelope and endoplasmic retic-
ulum with anti-FLAP and anti-5-LO could not be the result
of nonspecific interactions of either the primary IgG or the
gold probe with an unidentified component within these com-
partments .
Cryosections ofboth activated and resting leukocytes were
also incubated with preimmune IgG and the appropriate col-
loidal gold probes. In every case, no significant labeling of
the nuclear membrane, the plasma membrane or any other
cellular structure or compartment was observed when sec-
tions were labeled with preimmune IgG (data not shown) .
Another control experiment that demonstrated the speci-
ficity of the labeling patterns observed with anti-FLAP and
anti-5-LO was to preincubate the primary antibodies with
the appropriate free antigen before incubation with cryosec-
tions. The percent inhibition was then calculated by dividing
the number ofgold particles/tim nuclear membrane counted
on sections incubated with antibodies preincubated with free
antigen by that obtained from sections incubated with un-
treated antibody. When anti-FLAP was preincubated with
5 ug/ml of the appropriate FLAP peptide, labeling was re-
duced by >90% . When anti-5-LO was preincubated with
5Ag/ml recombinant 5-LO, -75% ofthe labeling was elim-
inated (Table 4) .
An additional control for antibody specificity was obtained
by observing cells present as contaminants in leukocyte prepa-
rations that are not known to contain significant amounts
of either FLAP or 5-LO. T and B lymphocytes in particular
have been reported to contain very little, if any, of either of
these proteins (7) . Lymphocytes are readily distinguished in
our cryosections by their large round nucleus and sparse
cytoplasm. Cells ofthis morphology in our preparations were
completely devoid of any detectable FLAP or 5-LO im-
munolabeling . In a related, separate experiment, we were also
unable to immunolabel a human cytotoxic T cell line (desig-
nated Q31) with either 5-LO orFLAP IgGs (data not shown) .
A final control for antibody specificity was provided by
the effect ofA23187 on the localization of 5-LO. Our initial
Figure 4 .
￿
Double immunogold labeling of 5-LO (10-nm gold, arrows) and FLAP (5-nm gold, arrowheads) on ionophore-activated monocyte. Note
that both labels are observed within the lumen of the nuclear envelope. Also notice that in some regions the labels are randomly distributed along
this compartment but are occasionally clustered together (boxed area) . Both labels are also observed associated with endoplasmic reticulum cisternae
(er) . Neither label is observed over the cytoplasmic ground substance . These specimens were prepared by incubating sections of activated leukocytes
with a mixture of mouse anti-5-LO and rabbit anti-FLAP, washing, and then incubating with a mixture ofGAM 10 and GAR 5 . Nuc, nucleus,
gr, granule, bar, 100 run.
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5-Lipoxygenase and 5-Lipoxygenase-activating Protein in Nuclear EnvelopeTable 4.
￿
Inhibition of Antibody Labeling by Preincubation with Excess Free Antigen`
Antibody
only
Anti-FLAP
￿
12.9 ± 4.7 (6)
Anti-5-LO
￿
13.3 ± 3 .4 (6)
' Data presented as the mean number of particles/pm ± SD (number of cells counted) .
experiments demonstrated that in resting cells it was virtu-
ally impossible to immunolabel this enzyme, whereas after
5 min of ionophore activation, 5-LO could be readily visual-
ized within the lumen of the nuclear envelope and endoplasmic
reticulum . Since the same reagents were used in either case,
the change in labelingwould most likely have been the result
ofa specific event that occurred as a result of activation. This
event was most probably the previously well described trans-
location of5-LO from a 100,000-g supernatant form in resting
cells to a membrane-associated form in activated cells (4, 33) .
Figure 5 .
￿
Immunolocalization of CD18 on an activated neutrophil . The
gold immunolabel is observed along the plasma membrane (pm, anow-
heads) where it is more often observedon microvilli (mv) but is also present
in areas between microvilli. Immunoreactive CD18 is also occasionally ob-
servedwithinsmall membrane bound cytoplasmic granules (avows) . Label
is not associated with the nuclear envelope (ne) or the endoplasmic retic-
ulum (er), nor are the gold particles found over the cytoplasmic ground
substance or within the nuclear matrix . Background label outside of the
cell is very rarely observed . Nuc, nucleus, bar, 100 urn.
1943
￿
Woods et al .
Discussion
Antibody plus
￿
Percent
free antigen
￿
inhibition
1.1 ± 0.4 (6)
￿
91.4%
3.5 ± 0.5 (6)
￿
73.3%
Our immunolocalization data demonstrated that in iono-
phore-activated monocytes and PNIN's, bothFLAP and 5-LO
were localized in the lumen of the nuclear envelope. In addi-
tion, except for very weak labeling of the endoplasmic retic-
ulum that may represent newly synthesized protein in the
biosynthetic pathway, neither protein could be detected in
any other cell compartment or along the plasma membrane.
In resting cells, the FLAP distribution was identical to that
observed in activated cells. In contrast, sections of resting
or sham-treated leukocytes incubated with anti-5-LO IgG
did not display any detectable gold label along the nuclear
envelope, endoplasmic reticulum, or plasma membrane, or
within the Golgi complex, other membrane bound organelles,
or over the cytoplasmic ground substance. However, there
were occasionally a few gold particles observed over the eu-
chromatin region within the nucleus . The subcellular frac-
tionation of resting leukocytes into nuclear and nonnuclear
fractions also demonstrated that the vast majority of the total
cellularFLAP protein was associated with the nuclear mem-
brane . Our observation that 5-LO translocates to the perma-
nent site ofFLAP residence after activation, combined with
the literature reporting thatFLAP is required for in vivo for-
mation ofleukotrienes (15-17), demonstrate that the nuclear
envelope comprises the intracellular site where 5-LO and FLAP
act on arachidonic acid to form 5-HPETE and LTA4 . These
data further suggest that the morphological correlate of the
biochemically-defined translocation event (14, 33) is the move-
ment of 5-LO from a nonsedimentable location to the nu-
clear envelope.
This conclusion is supported by biochemical evidence that
makes it clear that in several cell types the nuclear envelope
itself is the principle source of arachidonate for eicosanoid
synthesis. Eicosanoids are the family ofmolecules derived from
arachidonic acid and include the 5-LO products i .e ., leu-
kotrienes, as well as products of cyclooxygenase, i .e ., pros-
taglandins . Electronmicroscopic autoradiography of a mouse
fibrosarcoma cell line has shown that [3H]arachidonic acid
is most rapidly incorporated into the nuclear membrane (37)
and further that recently incorporated arachidonate is most
efficiently utilized for eicosanoid synthesis. Similarly, when
[ 14C]arachidonate was incorporated into mouse fibroblasts,
cell fractionation experiments demonstrated that this label
was incorporated most rapidly into a nuclear fraction andthat this fraction provided the bulk ofthe material that could
be subsequently incorporated into eicosanoids in response to
bradykinin stimulation (38). Thus, it would seem likely that
the enzymes required for the initial step of eicosanoid syn-
thesis would be localized alongthe nuclear envelope. Indeed,
prostaglandin endoperoxidase synthase 1 and 2 has been local-
ized in mouse 3T3 fibroblasts by indirect immunofluores-
cence to the nuclear envelope and ectoplasmic reticulum (39) .
The observation that the nuclear envelope is a key site of
eicosanoid metabolism is not widely understood. Indeed, in
many preparative procedures, the implicit assumption is that
the nuclear fraction can be discarded in the process ofpreparing
cell-free homogenates. In particular, in the field of leukotriene
research, there are several articles (33, 40, 41) on the bio-
chemistry of 5-LO metabolism in which cells were first
homogenized and the 10,000-g pelletable material discarded
before analysis ofsubsequent subcellular fractions. However,
our results indicate that by discarding the low speed pellet
before analysis of activated leukocytes, a significant portion
of the totalcellular 5-LO must also have been discarded, thus
adversely affecting the ability to understand the biology of
the processes under study.
The apparent difficulty in visualizing the intracellular dis-
tribution of 5-LO in resting cells may be an indication of
the lack of an association ofthis protein with any membrane,
cytoskeletal, or other elements that are retained in the final
ultrathin frozen sections. Since the sections were cut before
incubation with antibodies, this result suggests that in resting
cells 5-LO was neither fixedin place itselfnor was it associated
with a fixed structure, but rather the majority of this protein
was washed out of the sections during the blocking, anti-
body incubation, and washing steps. This should not be sur-
prising in that sequence analysis of 5-LO provides no indica-
tion ofeither hydrophobic domains that may associate directly
with a lipidbilayer, nor ofleader sequences that would mediate
translation on rough endoplasmic reticulum (42). In addi-
tion, 5-LO has shown no evidence of isoprenylation or phos-
phorylation, which could also potentially mediate membrane
or cytoskeletal associations (our unpublished observations).
Alternately, it may not have been possible to visualize 5-LO
in resting cells because the particular epitopes that bind the
anti-5-LO antibody used in these experiments were masked,
or because fixation cross-linked these epitopes (in resting cells
only) in such a way that the antibodies could not bind. In
any event, activation leads to a fundamental change in the
ability of anti-5-LO antibodies to label ultrathin frozen sec-
tions and this property correlates very well with previous
reports describing the "translocation" of 5-LO from a cyto-
solic to a membrane fraction (14, 33).
Our immunolocalization experiments utilized a novel com-
bination offixation techniques that has not previously been
described. We found that the combination of a very brief
fixation in 0.05% glutaraldehyde/3.5% paraformaldehyde
during which the cells were heated to 45°C by microwave
irradiation (originally described by Dvorak et al. [28]), fol-
lowed by several washes and an overnight incubation at 4°C
in PLP fixative (29) yielded a superior combination of re-
tained antigenicity and well-preserved ultrastructure. In par-
ticular this scheme preserved the content of many ofthe PMN
granules, which are often lost with other fixation techniques.
We compared this procedure with other protocols previously
utilized to preserve PMN for ultrastructural immunolocali-
zation experiments. Alternate procedures included 0.05-1.0%
glutaraldehyde in phosphate buffer for 30 min at 4°C (34)
and combinations of glutaraldehyde and paraformaldehyde
incubated at 4°C or 23°C for 30 min (36). These procedures
were less effective than the final glutaraldehyde/paraformalde-
hyde microwave/PLP protocol used here.
Immunogold labeling of ultrathin frozen sections has a
significant advantage over other postfixation immunolabeling
techniques. When labeling ultrathin frozen sections, accessi-
bility to intracellular compartments is obtained by virtue of
the fact that membrane bound compartments are cut open.
Thus, antibody probes have ready access to epitopes on ei-
ther side of any membrane bound compartment. However,
since the sections are incubated with the primary antibodies
after fixation, there remains the possibility that fixation of
critical epitopes may interfere with antibody recognition. Ex-
periments in which cells were incubated with anti-FLAP or
anti-5-LO antibodies before fixation were carried out to ad-
dress this possibility. The results ofthese experiments showed
that surface bound gold label could not be detected on sec-
tions of cells incubated with either antibody before fixation.
However, if these same sections were incubated with addi-
tional anti-FLAP or anti-5-LO after sectioning the nuclear
envelope was clearly labeled. When interpreting these results
it must be noted that the anti-FLAP antibody used in these
experiments was an anti-peptide antibody that recognizes
a discrete region ofthe FLAP amino acid sequence. Our results
clearly show that this region ofFLAP is oriented toward the
lumen of the nuclear envelope. Thus, unless the protein reverses
its orientation through the lipid bilayer, it would be expected
that if FLAP were present in the plasma membrane the anti-
body binding domain should be exposed to the extracellular
medium and thus be available to bind externally applied anti-
body before fixation and subsequent sectioning. This con-
siderationis not a factor in interpreting the results with anti-5-
LO since this probe was a polyclonal antibody that would
be expected to recognize multiple epitopes at various random
locations on the protein. These data thus demonstrate that
FLAP and 5-LO are not detectable on the plasma membrane,
and also suggest that fixation does not interfere with the ability
of the anti-FLAP antibodies used in our experiments to bind
FLAP.
The observation that the nuclear envelope is the intracel-
lular site at which 5-LO and FLAP act is consistent with
the observed correlation between the potency of 5-LO and
FLAP inhibitors and theirlipophilicity (43). MK-886, a first
generation leukotriene synthesis inhibitor that binds to FLAP,
is lipophilic and has been shown to partially block increased
urinary LTE4 excretion after antigen challenge in asthmatics,
and to partially inhibit antigen-induced bronchoconstriction
(44). MK-591, a more intrinsically potent FLAP inhibitor
is also lipophilic, and has been shown to completely inhibit
LTB4 production in whole blood assays and urinary LTE4
production, after a single dose in normal human volunteers
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lates to thecapacity ofpotentialleukotriene inhibitors to pene-
trate cell membranes and thereby gain access to the nuclear
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